For diabetes patients, inhaled insulin is shown just as effective as injections and pumps [FOX News]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: FOX News
Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as effective. In a study led by Dr. Irl B. Hirsch, M.D., medical director of the Diabetes Care Center of the University of Washington Medical Center, an inhaled form of insulin — similar to an asthma inhaler — worked just as well as injections or pumps to control type 1 diabetes. The research was presented last week at the American Diabetes Association (ADA)'s 84th Scientific Sessions in Orlando, Florida. The clinical trial tested a product called Afrezza, an inhaled basal insulin made by MannKind Corporation in California. Afrezza, the only inhaled insulin on the market, has been available since getting FDA approval in June 2014. "In those with type 1 diabetes, insulin is required for survival ," Hirsch told Fox News Digital in an interview. "With continuous glucose sensing, gluco
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- Developments in Nontuberculous Mycobacterial Infections Pipeline for 2024 [Yahoo! Finance]Yahoo! Finance
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease [Yahoo! Finance]Yahoo! Finance
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewswire
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswire
- MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
MNKD
Earnings
- 8/7/24 - Beat
MNKD
Sec Filings
- 9/4/24 - Form 4
- 9/3/24 - Form 144
- 8/30/24 - Form 4
- MNKD's page on the SEC website